|Last Price$21.04||Day Change (%)0.29%|
|Open Price$21.07||Day Change ($)0.06|
|Day Range20.77–21.22||52-Week Range12.41–21.22|
As of Thu 04/17/2014 04:14 PM EST | USD
Pfizer’s Novel CDK 4/6 Inhibitor Palbociclib plus Letrozole Significantly Prolonged Progression-Free Survival in Patients with Advanced Breast Cancer
The Fed's taper dominated the headlines in August, but investors were looking for undervalued stocks, yield, and international opportunities.
Micros' market-leading position in enterprise application software, hardware, and services supports its narrow economic moat and will protect the company from emerging threats for a significant time.